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Abstract
Whether environmental contaminants increase breast
cancer risk among women on Long Island, NY, is
unknown. The study objective is to determine whether
breast cancer risk is increased in relation to
organochlorines, compounds with known estrogenic
characteristics that were extensively used on Long Island
and other areas of the United States. Recent reports do
not support a strong association, although there are
concerns with high risks observed in subgroups of
women. Blood samples from 646 case and 429 control
women from a population-based case-control study
conducted on Long Island were analyzed. No substantial
elevation in breast cancer risk was observed in relation
to the highest quintile of lipid-adjusted serum levels of
p,p-bis(4-chlorophenyl)-1,1-dichloroethene (DDE) [odds
ratio (OR), 1.20 versus lowest quintile; 95% confidence
interval (CI), 0.76–1.90], chlordane (OR, 0.98; 95% CI,
0.62–1.55), dieldrin (OR, 1.37; 95% CI, 0.69–2.72),
the sum of the four most frequently occurring PCB
congeners (nos. 118, 153, 138, and 180; OR, 0.83; 95%
CI, 0.54–1.29), and other PCB congener groupings.
No dose-response relations were apparent. Nor was
risk increased in relation to organochlorines among
women who had not breastfed or were overweight,
postmenopausal, or long-term residents of Long Island;
or with whether the case was diagnosed with invasive
rather than in situ disease, or with a hormone receptor-
positive tumor. These findings, based on the largest
number of samples analyzed to date among primarily
white women, do not support the hypothesis that
organochlorines increase breast cancer risk among
Long Island women.
Introduction
Residents of Long Island, New York, have long been concerned
about the effects of environmental pollutants, particularly the
widespread spraying of the persistent organochlorine pesticide
DDT3 (1), which was used on Long Island primarily for control
of mosquitoes and gypsy moths before its ban in the United
States in 1972. These concerns, coupled with the community’s
more recent focus on the high incidence rates of breast cancer
observed in Nassau and Suffolk counties4 (2), led to federal
legislation mandating that an epidemiological study be con-
ducted to address these and other environmental health issues
(Public Law 103-43, June 10, 1993).
Organochlorines (DDT and its metabolite DDE, the indus-
trial chemical PCBs, the termiticide chlordane, the pesticide
dieldrin, and others), have known estrogenic and antiestrogenic
characteristics in vivo and in vitro (3). The important influence
of estrogen in breast cancer development (4, 5) suggests that
exposure to these contaminants, which have been classified as
either known or suspected carcinogens, could affect the initia-
tion or promotion of breast carcinogenesis (3, 6–8).
An increased risk of breast cancer in relation to organo-
chlorines was observed in several early as well as later reports
(9–16). However, most epidemiological studies (17–35), in-
cluding others in the Long Island-New York City area (36–38),
have not been strongly supportive of a relationship between
DDT or PCBs and the incidence of breast cancer. Remaining
concerns include recent reports of subgroup effects that become
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evident when the association between breast cancer and or-
ganochlorines is stratified by breastfeeding history (39, 40),
menopausal status (16), or body size (33) and when cases are
categorized on selected characteristics of the tumor, such as
stage of disease (41) or hormone-receptor status (12), or with
selected exposures including specific PCB congeners (15, 37,
39, 42) or dieldrin (23). The study reported here is based on
data collected as part of the Long Island Breast Cancer Study
Project, a population-based case-control investigation (43) with
large numbers of biological samples available for analyses to
facilitate exploration of possible subgroup effects.
Materials and Methods
The investigation was undertaken after approval from partici-
pating institutional review boards and in accordance with an
assurance filed with and approved by the United States Depart-
ment of Health and Human Services. Details of the study
methods have been described previously (43).
Study Subjects. Eligible cases included female residents of
Nassau and Suffolk counties, age 20 years or older, who spoke
English, and were newly diagnosed with in situ or invasive
breast cancer between August 1, 1996, and July 31, 1997. Cases
were identified through pathology laboratories of all of the
hospitals in the Long Island area. Controls were female resi-
dents of the same two counties and were frequency matched by
5-year age group to the expected age distribution of the cases.
Controls were identified using random digit dialing (44) for
those under age 65 years, and Health Care Financing Admin-
istration rosters for those ages 65 years or greater.
Participants included 1508 cases and 1556 controls. Ex-
cluding unlocatable women (for whom final study eligibility
could not be determined), the overall interview response rates
are 83.2 and 68.0%, respectively. Participants ranged in age
from 24 to 96 years, and the proportion who identified them-
selves as white was 93%; 5% were black, and 2% were other;
4% of participants also identified themselves as of Hispanic
ethnicity, regardless of race (43).
Exposure Assessment. Signed informed consent was obtained
from each participant prior to data collection. The 2-h ques-
tionnaire was administered in person by a trained interviewer.
Nearly three-quarters of case and control participants who
completed the main interview donated a nonfasting blood sam-
ple (73.0 and 73.3%, respectively). A sample of cases with
invasive cancer who provided a prechemotherapy blood sample
also donated a second, postchemotherapy, sample (n  139, or
88.0% of the women approached), because of an earlier concern
regarding the effect of chemotherapy on organochlorine levels
(45).
In a previous analysis (43), established risk factors for
breast cancer that were also found to increase breast cancer risk
among Long Island residents included lower parity, late age at
first birth, little or no breast feeding, and family history of
breast cancer. These same factors were found to increase the
risk for breast cancer among respondents who donated blood
(data not shown). Factors that were found to be associated with
a decreased likelihood that a respondent would donate blood
include increasing age (1% decrease for each yearly increase in
age) and past smoking (25% decrease); factors associated with
an increased probability include white (65% increase) or other
race (74% increase), alcohol use (28% increase), ever breastfed
(47% increase), ever use of hormone replacement therapy (63%
increase), and ever had a mammogram (51% increase). Case-
control status was not a predictor of blood donation among
respondents (43).
Subjects Selected for Laboratory Assays of Organochlo-
rines. Blood samples were randomly selected for the labora-
tory assays from among participants who donated a sample with
a serum blood volume of 1.5 ml. As shown in Table 1, the
number of samples randomly selected included 415 cases with
invasive breast cancer and 406 controls. All of the samples with
sufficient blood volume donated by African-American subjects
who were not selected during the random selection process
were assayed (n 5 cases and 23 controls). All of the 184 cases
diagnosed with in situ disease who had donated a blood sample
were also assayed. Laboratory samples were selected on the
basis of the initial case diagnosis. However, by the end of the
field activities when the data were more completely character-
ized, selected blood samples that were originally categorized as
donated by cases with invasive cancer were determined to have
been donated by women with in situ disease (n 56), and those
originally categorized as in situ were determined to be invasive
(n 42). In addition, the second blood samples donated by 139
cases diagnosed with invasive breast cancer were also analyzed.
Laboratory Assays. The method of Brock et al. (46) was used
to determine serum organochlorine levels including p,p-DDE,
p,p-DDT, oxychlordane, trans-nonachlor, dieldrin, and 24






(n)Invasive In situ All
(A) Respondent to main questionnaire 1508 1556 3064
(B) Blood donor 1102 1141 2243
(C) Blood samples selected for organochlorine compound assays ( E  F) 601 184 785 429 1214
(D) Reason for selection:
(E) Random samplea 415 415 406 821
(F) Specifically selected ( G  H  I  J  K) 186 184 370 23 393
(G) In situ cases selected 128 128
(H) African Americans not randomly selected 5 23 28
(I) Selected as in situ, but invasive 42 42
(J) Selected as invasive, but in situ 56 56
(K) Donated second sample 139 139
(L) Blood samples included in most statistical analyses ( C  K)b 462 184 646 429 1075
a All of the samples donated by in situ cases with sufficient amounts of blood/DNA were selected for analyses (see “Materials and Methods”).
b Excludes second samples (see “Materials and Methods”).
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PCB congeners (nos. 15, 28, 74, 66, 56, 101, 99, 82, 118, 146,
153, 105, 138, 178, 187, 183, 167, 174, 177, 156, 180, 170, 199,
203). Limits of detection were 0.2 ng/ml for DDE and DDT
and 0.07 ng/ml for individual PCB congeners based on 3  the
SD (47) of the levels found in the lowest quality control plasma
pool. When the serum pool and blanks were considered to-
gether (48) the limit of detection for the PCB congeners was
0.01–0.1 ng/ml; the instrumental limit of detection based on a
peak:noise ratio of 3, was 0.01–0.03 ng/ml for tetra- through
hepta-chlorobiphenyls, using 1–1.5 ml of plasma. This estimate
is similar to that reported recently in other studies (49). The
laboratory was blind with respect to any information concern-
ing study subjects; all individually matched and multiple spec-
imens from the same individual were analyzed in the same
laboratory batch. Three serum pools, created from outdated
bloodbank plasma, were analyzed for quality control purposes
over the course of the analyses. Results were: for the low
(unfortified) pool (n  95) DDE 2.3 ng/ml, CV 35%, and PCB
(as the sum of the 4 major peaks) 1.6 ng/ml, CV 40%; for the
medium pool (n  66) DDE 16 ng/ml, CV 15%, and PCB 6.0
ng/ml, CV 26%; for the high pool (n  35) DDE 28 ng/ml, CV
10%, and PCB 13 ng/ml, CV 19%. A medium-level pool was
also incorporated into the field samples in a blinded fashion;
results for 28 samples were: DDE 14 ng/ml, CV 16%, and PCB
4.2 ng/ml, CV 22%. Similar results were obtained for individ-
ual peaks and other organochlorines. Serum triglycerides and
cholesterol were determined by a commercial laboratory (Ni-
chols Institute/Quest Diagnostics, Teterboro, NJ).
Statistical Analyses. Positive and zero values of individual
organochlorine levels below the detection limit were set to the
lowest positive value for that compound observed in these
samples, rather than being assigned a censored value. Values
judged to be unreliable were coded as missing; the proportion
was low but varied with the specific compound (see “Appen-
dix”). Organochlorine values were adjusted for serum lipid
levels (triglycerides and total cholesterol) using the method of
Phillips et al. (50). Organochlorine distributions were skewed
(data not shown), and, thus, the values were log transformed on
a natural log scale. Comparisons of the paired first and second
blood draw among cases with serial blood donations were
conducted using the paired t test. There were no statistically
significant differences (P  0.10) in organochlorine compound
levels between samples taken before and after chemotherapy
(data not shown). The organochlorine results presented are,
therefore, based on the first blood draw of cases with multiple
samples or the only blood draw from cases with a single blood
sample. The assayed organochlorine levels included in the
statistical analyses are p,p-DDE, chlordane (the sum of oxy-
chlordane and trans-nonachlor), dieldrin, and the sum of the
four most frequently occurring PCB congeners among our
sample of Long Island women [Peak-4 PCBs  IUPAC nos.
118, 153, 138, 180, which together represent a mean (SD) of
49.42% (7.81%) of the sum of the 24 congeners assayed (total
PCBs)]. Statistical analyses were also conducted for the indi-
vidual four most frequently occurring congeners, Total PCBs,
as well as two other PCB groupings, which were grouped based
on toxicological activity and occurrence (37, 51). Extended
results based on Peak-4PCBs are reported; they did not sub-
stantially differ from the results based on other PCB measures
(data not shown). For the 85 subjects with missing data on the
Peak-4 PCB measure, which was limited to one or two of the
congeners, regression analysis was used to calculate the pre-
dicted values for the missing congeners from nonmissing val-
ues for the other Peak-4 PCB congeners. Results based on the
data with imputed values were not materially different from
those obtained from the data in which missing Peak-4 PCB
values were simply omitted (data not shown), and, thus, the
results based only on the former are shown. Similarly, the
number of missing values was higher for the DDT values than
for the DDE values. Results for DDE were not materially
different from those shown for DDT (data not shown), and only
the extended results based on DDE are shown. Multiple regres-
sion analyses (52) were conducted to determine those factors
that best predicted organochlorine levels in blood among the
control women.
Statistical comparisons of the geometric means of case and
control organochlorine levels in blood were conducted using
the unpaired Student t test. Unconditional logistic regression
was used to determine the ORs, and 95% CIs, for breast cancer
in relation to organochlorine compound levels, with adjust-
ments made for age (continuous) and for other potentially
confounding factors (52). The risk of breast cancer was esti-
mated in relation to organochlorines with the blood levels
categorized by tertiles, quartiles, quintiles, and deciles, and as
continuous variables. Results did not vary substantially with the
different cut points used (data not shown). Thus, for the main
effects of organochlorines, results shown are based on quintiles;
and for exploration of possible effect modification, results
shown are based on tertiles. To evaluate an apparent dose-
response association between breast cancer risk and a specific
organochlorine level, tests for trend were performed based on
comparing models with and without the exposure variable
entered as a continuous variable (53).
Factors considered either as potential predictors of organo-
chlorine compound levels of blood in multiple regression mod-
els or as potential confounders in the initial multivariate logistic
regression models include: age at reference, age at reference
squared, age at menarche, parity, number of live births, lacta-
tion, months of lactation, age at first birth, number of miscar-
riages, history of fertility problems, BMI at reference (defined
as date of diagnosis for cases and as date of identification for
controls), BMI at age 20, alcohol intake, cigarette smoking,
family history of breast cancer in a first-degree relative, history
of benign breast disease, oral contraceptive use, hormone re-
placement use, race, Hispanic ethnicity, education, marital sta-
tus, religion, county of residence at the reference date, total
years of residence on Long Island, and age first moved to Long
Island. The final multivariate models shown include those fac-
tors that remained in a best fitting model, which was developed
by starting with a model that included all covariates and then
excluding those that did not improve the overall fit as measured
by the 2 log likelihood ratio test (53).
Potential effect modification, on a multiplicative scale,
was formally assessed by comparing the multivariate models
with and without cross-product terms (53). Potential effect
modifiers considered include: BMI at age 20, BMI at reference,
breastfeeding history, menopausal status, length of residence on
Long Island, and age at reference. To determine breast cancer
risk with cases categorized by tumor stage of disease (in situ
versus invasive), or ER and PR, unordered polytomous logistic
regression (53) was performed. Because of the limited number
of cases and controls for whom dieldrin assessments were
available, extended analyses were not conducted in relation to
this compound.
The statistical analyses were based on all of the cases and
controls who were randomly selected for the assays, as well as
those who were specifically selected. The analyses were re-
peated restricting the sample to those cases and controls who
were randomly chosen to have their blood assayed (e.g., for the
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DDE analyses, cases n 415 and controls n  406). Results
from these latter models were nearly identical to the former, and
are not presented.
Results
In regression models, factors that were found to significantly
predict DDE levels in blood among control women included
age at reference date, alcohol consumption, BMI at age 20,
number of pregnancies, months of hormone replacement use,
race, and religion. The comparable factors for DDT were age at
reference date, race, and religion, and for Peak-4 PCBs, were
age at reference date, number of pregnancies, marital status,
race, religion, years of residence on Long Island, weight at age
20, and weight at reference date.
Table 2 shows the geometric means of blood levels of
DDE, DDT, Peak-4 PCBs (summed and individually), chlor-
dane, and dieldrin, unadjusted and adjusted for lipid levels by
case-control status. Case-control differences in organochlorine
levels were minimal. Table 3 presents the age-adjusted and
multivariate-adjusted ORs for breast cancer in relation to these
same organochlorine compounds. Slightly elevated, but non-
significant, multivariate-adjusted ORs were noted for the high-
est quintile, as compared with the lowest, of DDE (1.20; 95%
CI, 0.76–1.90), DDT (1.15; 95% CI, 0.74–1.79), and dieldrin
(1.37; 95% CI, 0.69–2.72). No consistent elevation in risk was
noted with Peak-4 PCBs, or with chlordane. No dose-response
relation was evident for any of the organochlorines (test for
trend P  0.05).
The association between organochlorines and breast can-
cer stratified by parity and lactation is shown in Table 4.
Among nulliparous women, a 2-fold elevation in risk was
noted in relation to the second and third tertiles of chlordane;
however, the cell sizes were small and the estimates of effect
were unstable. No heterogeneity in risk was noted in relation to
the highest levels of DDE, Peak-4 PCBs, or chlordane among
parous women regardless of their breastfeeding history.
Whether BMI at reference modified the association be-
tween organochlorines and breast cancer risk is shown in Table
5; no substantially elevated risk was observed among women
for any level of BMI. In Table 6 are the multivariate-adjusted
ORs for breast cancer in relation to organochlorines within
strata of age at reference date, menopausal status, and length of
residence on Long Island. No substantial elevations in risk in
relation to DDE, chlordane, or Peak-4-PCBs were noted for
women under age 65 years and over 65 years or among pre- and
postmenopausal women. Among women who had lived on
Long Island less than 15 years, risks were nonsignificantly
increased in relation to the highest tertile of exposure for DDE
(multivariate-adjusted OR, 2.13, as compared with lowest ter-
tile, 95% CI, 0.81–5.60) and Peak-4 PCBs (multivariate-
adjusted OR, 1.52; 95% CI, 0.64–3.62); CIs are wide indicating
that the estimates are unstable. Among women who resided on
Long Island for 15 years or longer, no increased breast cancer
risks were observed in relation to any of the compounds ex-
amined. Also, when other cut points for length of residence
were considered, no substantial heterogeneity was observed
(data not shown).
Table 7 shows the multivariate-adjusted ORs for breast
cancer in relation to organochlorines with the cases grouped by
selected characteristics of the tumor. Risk did not vary with
stage of disease (in situ or invasive). With cases subdivided
based on the joint hormone receptor status of the tumor, no
substantial elevations were seen among cases with ERPR or
ERPR tumors. Among cases with ERPR tumors, nearly
a 2-fold risk increase was noted in relation to the highest tertile
of Peak-4 PCBs, and a 47% risk reduction was noted in relation
to chlordane. However, the corresponding CI intervals were
wide, and the tests for trend were not statistically significant
(P  0.64 and 0.75, respectively). Among case women with
ERPR breast cancer, a significant decrease was noted in
relation to Peak-4 PCBs (multivariate-adjusted OR, 0.46;
95% CI, 0.24 – 0.90), but the test for trend was not significant
(P  0.25).
Discussion
In this population-based case-control study conducted among
women on Long Island, there was little evidence of an increased
risk of breast cancer in relation to DDE, DDT, PCBs, chlor-
dane, or dieldrin. These findings are consistent with most recent
studies that have focused on DDT/DDE, PCBs, or chlordane
(17–38), but not all (9–16, 39). Our finding of no relation with
dieldrin is inconsistent with the single previous report (23).
Study limitations include a less than optimal response rate
among controls, particularly older controls (43), which has been
reported by others who conduct population-based studies (54)
or studies among older populations (55). We found no striking
heterogeneity in risk in relation to organochlorines when strat-
ified by age, which suggests that the higher rate of nonresponse
among older controls did not unduly influence our study results.
Also, as reported previously (43), an increased breast cancer
risk among these Long Island women was noted in relation to
several important established risk factors for breast cancer,
including lower parity, late age at first birth, little or no breast
feeding, and family history of breast cancer.
Table 2 Geometric mean (and geometric SD) serum levels of organochlorine compounds unadjusted and adjusteda for lipid levels among breast cancer cases and
controls, Long Island Breast Cancer Study Project, 1996–1997
Organochlorine
compound
Study population size (n) Unadjusted (ng/ml) Adjusted* (ng/g)
Cases Controls Cases Controls t test P Cases Controls t test P
DDE 643 427 4.31 (2.84) 4.07 (2.68) 0.36 671.96 (2.76) 645.74 (2.59) 0.52
DDT 633 418 0.44 (1.84) 0.43 (1.82) 0.54 68.98 (1.83) 69.32 (1.79) 0.89
Peak-4 PCBs 638 423 2.49 (1.72) 2.45 (1.76) 0.68 386.72 (1.69) 391.74 (1.74) 0.70
BZ118 638 423 0.35 (2.05) 0.36 (2.08) 0.98 55.13 (2.00) 56.47 (2.03) 0.59
BZ138 638 423 0.53 (2.56) 0.53 (2.53) 0.94 82.08 (2.54) 84.92 (2.52) 0.56
BZ153 638 423 0.98 (1.69) 0.96 (1.72) 0.61 151.68 (1.66) 153.20 (1.70) 0.76
BZ180 638 423 0.51 (1.79) 0.49 (1.83) 0.25 79.66 (1.75) 78.63 (1.79) 0.70
Chlordane 597 397 0.61 (2.39) 0.60 (2.07) 0.62 94.58 (2.28) 95.90 (1.95) 0.77
Dieldrin 181 148 0.12 (2.41) 0.12 (2.18) 0.83 20.40 (2.34) 21.29 (2.16) 0.64
a Adjusted using method 2 as described by Phillips et al. (50).
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Results from a previous analysis (43) indicated that there
were some differences noted among our study participants who
donated blood samples as compared with those who did not.
Women were less likely to donate blood if they were older or
a past smoker, and more likely if they were white, ever used
alcohol, ever breastfed, ever used hormone replacement or oral
contraceptives, or ever had a mammogram (43). These factors
were not found to substantially confound or modify the relation
between breast cancer risk and organochlorines in these data,
which suggests that the observed differences between blood
donors and nondonors did not substantially affect our study
results.
A further consideration stems from a recent report of a
3-fold increased breast cancer risk in relation to DDT, as
assessed by repeated measurement of serum levels (15). Re-
peated assessments may better reflect an individual’s true body
Table 3 Age-adjusted and multivariate-adjusteda ORs and 95% CIs for breast cancer in relation to log-transformed serum organochlorine levels adjustedb for serum




(ng/gm lipid) Cases, n Controls, n
Age-adjusted Multivariate-adjusteda
OR (95% CI) OR (95% CI)
DDE 	306.91 122 84 1.00 1.00
306.91–515.00 110 83 0.84 (0.56–1.26) 0.88 (0.58–1.32)
515.01–798.24 127 84 0.91 (0.60–1.36) 0.94 (0.63–1.43)
798.25–1,373.48 123 85 0.82 (0.54–1.25) 0.92 (0.60–1.42)
1,373.49–11,818.78 150 83 0.95 (0.62–1.46) 1.20 (0.76–1.90)
DDT 	44.79 129 81 1.00 1.00
44.79–61.43 96 82 0.72 (0.48–1.08) 0.69 (0.44–1.07)
61.44–81.20 123 82 0.94 (0.63–1.39) 1.04 (0.66–1.63)
81.21–108.03 134 82 1.00 (0.67–1.48) 1.16 (0.75–1.80)
108.03–747.92 133 82 0.97 (0.66–1.44) 1.15 (0.74–1.79)
Peak-4 PCBs 	262.57 134 83 1.00 1.00
262.58–325.56 112 83 0.76 (0.51–1.14) 0.76 (0.51–1.15)
325.57–427.78 132 83 0.87 (0.58–1.29) 0.90 (0.60–1.35)
427.79–586.74 123 83 0.77 (0.51–1.15) 0.82 (0.54–1.24)
583.74–3,287.34 126 83 0.72 (0.47–1.10) 0.83 (0.54–1.29)
BZ118 	32.66 134 83 1.00 1.00
32.66–46.45 133 83 0.96 (0.65–1.41) 0.96 (0.64–1.42)
46.46–63.39 109 83 0.74 (0.50–1.11) 0.77 (0.52–1.16)
63.40–94.94 114 83 0.72 (0.48–1.09) 0.82 (0.54–1.24)
94.95–1,015.88 136 83 0.79 (0.52–1.20) 0.93 (0.60–1.43)
BZ138 	49.38 117 82 1.00 1.00
49.38–81.09 153 83 1.24 (0.84–1.84) 1.26 (0.85–1.88)
81.10–111.15 129 83 1.00 (0.67–1.49) 1.04 (0.69–1.55)
111.16–156.22 106 83 0.79 (0.52–1.19) 0.80 (0.52–1.21)
156.23–936.75 120 83 0.83 (0.54–1.26) 0.96 (0.63–1.48)
BZ153 	103.75 140 82 1.00 1.00
103.75–130.02 115 83 0.74 (0.50–1.10) 0.75 (0.50–1.13)
130.03–170.81 132 83 0.84 (0.56–1.24) 0.85 (0.57–1.27)
170.82–227.54 107 83 0.64 (0.43–0.97) 0.68 (0.45–1.03)
227.55–1,130.08 132 83 0.75 (0.50–1.13) 0.86 (0.56–1.32)
BZ180 	51.49 123 82 1.00 1.00
51.49–69.70 121 83 0.89 (0.60–1.33) 0.87 (0.58–1.31)
69.71–87.41 117 83 0.83 (0.55–1.24) 0.81 (0.54–1.23)
87.42–120.37 128 83 0.88 (0.58–1.32) 0.89 (0.58–1.34)
120.38–721.29 134 83 0.86 (0.56–1.31) 0.95 (0.62–1.46)
Chlordane 	62.47 109 78 1.00 1.00
62.48–85.68 99 78 0.84 (0.55–1.28) 0.88 (0.57–1.35)
85.69–111.42 107 78 0.89 (0.59–1.36) 0.97 (0.64–1.49)
111.43–162.47 145 78 1.12 (0.74–1.70) 1.20 (0.78–1.84)
162.48–473.08 126 78 0.88 (0.56–1.37) 0.98 (0.62–1.55)
Dieldrin 	14.96 37 29 1.00 1.00
14.97–20.90 38 27 1.10 (0.55–2.19) 1.19 (0.59–2.41)
20.91–26.67 32 29 0.87 (0.43–1.75) 0.91 (0.45–1.84)
26.68–33.45 22 28 0.62 (0.30–1.30) 0.64 (0.30–1.35)
33.46–179.29 46 29 1.28 (0.65–2.52) 1.37 (0.69–2.72)
a DDE, Peak-4 PCB, and individual PCB analyses were adjusted for age, race, history of fertility problems, and history of benign breast disease. Chlordane analyses were
adjusted for age, race, history of fertility problems, and gravidity. DDT analyses were adjusted for history of benign breast disease, history of fertility problems, gravidity,
and race. Dieldrin analyses were adjusted for age and race.
b Adjusted using method 2 as described by Phillips et al. (50).
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burden over time, given the possible interindividual variations
in metabolizing these compounds. In a pilot study that we
conducted before the initiation of our large case-control study,
low-dose ambient exposures were not found to result in variable
intraindividual blood levels over a short-period of time, and a
single measurement was determined to be sufficient (56). Or-
ganochlorine levels among the United States population have
been decreasing over time (34, 57). It is possible that there were
substantial variations in exposure levels in the distant past.
However, variations in individual metabolism could possibly
result in low variability in recently measured organochlorine
levels.
Subgroup Effects. In our study, there was no substantial var-
iation in risk in relation to breastfeeding and menopausal status,
nor with the cases subdivided by in situ or invasive disease. In
contrast, significant risk reductions were observed in relation to
Peak-4 PCBs for women who were 65 years or older at diag-
nosis, in relation to chlordane among case women with
ERPR tumors, and in relation to PCBs among breast cancer
cases with ERPR tumors. However, even with our large
overall sample size, the number of subjects on whom each of
these subgroup effects is based were small, yielding unstable
estimates of effect. Furthermore, none of the ERPR subgroups
in which reduced ORs were observed were among those that we
had hypothesized a priori as either potentially high- or low-risk
groups. Consequently, their importance is difficult to interpret,
and some, or even all, may be indistinguishable from chance.
PCB Congeners. Recent concern has focused on whether
breast cancer risk may be elevated in relation to specific PCB
congeners or to congeners grouped by biological activity
(estrogen-like, antiestrogen-like, or other), rather than a meas-
ure that simply sums all PCBs together, which could obscure
important associations (3, 49, 51, 58). When individual conge-
ners have been examined, mean differences between cases and
controls have been noted for congeners 74, 138, and 183 (38);
for 138 and 118 (15, 25), and for 118 and 156 (49). After
stratifying by menopausal status, elevated risks have been noted
in relation to congeners 105 and 118 among premenopausal
women and 170 and 180 for postmenopausal women (40), or
among postmenopausal women in relation to congeners 77,
126, and 169 (42). Findings on these or closely correlated
congeners have not been corroborated in the data reported
here or by others (29, 31, 33–37). Individual PCB congeners
are highly correlated with each other (37, 38, 59), which
complicates disentangling any risks associated with either
individual or grouped congeners (59).
Breastfeeding. The earlier report of an elevated breast
cancer risk in relation to serum PCB levels among postmeno-
pausal women with no history of breastfeeding (39) is consist-
ent with the observation that pesticide residues are removed
from the breast and excreted in human breast milk during
lactation (60). In the data reported here, and by others (31, 33,
34), there was little effect of breastfeeding on the association
between organochlorines and breast cancer.
Table 4 Multivariate-adjusteda ORs and 95% CIs for breast cancer in relation to lipid-adjustedb log-transformed serum levels of organochlorine compounds stratified






(ng/g lipid) Cases, n Controls, n
Multivariate-adjusted
OR (95% CI)
Nulliparous women DDE 	458.25 26 19 1.00
458.26–951.82 29 9 1.69 (0.59–4.82)
951.83–11,818.78 25 17 0.75 (0.24–2.40)
Peak-4 PCBs 	308.34 26 18 1.00
308.35–472.45 21 8 1.55 (0.53–4.56)
462.46–3,287.34 32 19 1.22 (0.42–3.50)
Chlordane 	79.18 21 22 1.00
79.19–125.53 22 9 2.36 (0.84–6.68)
125.54–473.08 28 11 2.83 (0.93–8.65)
Parous women, never breastfed DDE 	458.25 89 57 1.00
458.26–951.82 105 81 0.82 (0.52–1.28)
951.83–11,818.78 136 76 1.14 (0.70–1.84)
Peak-4 PCBs 	308.34 113 64 1.00
308.35–472.45 107 77 0.74 (0.48–1.14)
462.46–3,287.34 107 72 0.79 (0.50–1.26)
Chlordane 	79.18 83 59 1.00
79.19–125.53 100 68 1.02 (0.64–1.63)
125.54–473.08 119 75 1.03 (0.64–1.65)
Parous women, ever breastfed DDE 	458.25 87 63 1.00
458.26–951.82 53 49 0.66 (0.38–1.13)
951.83–11,818.78 73 46 0.96 (0.51–1.80)
Peak-4 PCBs 	308.34 75 56 1.00
308.35–472.45 63 52 0.86 (0.51–1.44)
462.46–3,287.34 73 47 1.12 (0.63–2.00)
Chlordane 	79.18 74 48 1.00
79.19–125.53 64 51 0.77 (0.45–1.31)
125.54–473.08 65 45 0.79 (0.44–1.44)
a DDE and Peak-4 PCB analyses were adjusted for age, race, history of fertility problems, and history of benign breast disease. Chlordane analyses were adjusted for age,
race, history of fertility problems, and gravidity.
b Adjusted using method 2 as described by Phillips et al. (50).
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Body Size. Wolff and Anderson (61) suggested, based on
a pharmacokinetic model, that women with lower BMI had a
higher tissue concentration of DDE 1–2 decades earlier. A
positive association between current DDE or dieldrin levels and
body size has been observed in several studies (19, 21, 25, 62).
Wolff and Anderson (61) determined that the half-life of DDE
is longer among obese women than leaner women. Further-
more, in a recent population-based study, breast cancer risk in
relation to PCBs was higher in obese women (33). Thus,
whether organochlorines affect risk particularly among obese
or lean women deserves examination. In the data reported
here, body size did not appear to influence the relationship
between organochlorines and breast cancer risk, which is
consistent with results from the most recent report from the
Nurses’ Health Study (34) but not from one other report (33).
Menopausal Status and Hormone Receptor Status. After
age 50, breast cancer incidence rates decline among Japanese
women but rise among Western women (63). Recently, the
increasing incidence in Westerners has been shown to be re-
stricted to a rise in ERPR tumors (64), which are consid-
ered more hormonally sensitive than the other ERPR subtypes
(65). Three-quarters of newly diagnosed breast cancers occur
among women over age 50 (2); thus, exploration of whether
potential estrogen-related environmental risk factors differen-
tially affect women based on menopausal status or hormone
receptor status is indicated. An elevated breast cancer risk in
relation to organochlorine levels has been observed among
postmenopausal women (16) or among cases with ER
tumors (12). In contrast, a substantial increase in risk was not
found among postmenopausal women, older women, or
women diagnosed with ERPR or ERPR tumors in the
data reported here, or by others (20, 24, 34, 36, 37). In our
data, an increase in risk was observed among ERPR
subtypes in relation to PCBs. The lack of such an association
in other reports (34, 36, 37) and the lack of biological
plausibility, increases the likelihood that our observation is
a chance finding.
Stage of Disease. A recent investigation (41) observed an
increased risk of breast cancer among those with lymph node
invasion at diagnosis in relation to levels of DDE, DDT,
oxychlordane, trans-nonachlor, and PCB 153. Because of our
efforts to collect blood from cases before the onset of chemo-
therapy (43), we lacked detailed information on the final diag-
nosis by stage of disease beyond a classification as invasive or
in situ disease. In these data, we observed no substantial dif-
ferences in risk between in situ and invasive breast cancer in
relation to serum organochlorines, consistent with a recent
study by Zheng (31). Another recent study (66) reported a
decrease in breast cancer survival among women with higher
organochlorine levels. Further examination of the possibility
that organochlorines are associated with a more advanced stage
of disease and/or a worse prognosis appears warranted.
Table 5 Multivariate-adjusteda ORs and 95% CIs for breast cancer in relation to lipid-adjustedb log-transformed serum levels of organochlorine compounds stratified
by BMI among breast cancer cases and controls, Long Island Breast Cancer Study Project, 1996–1997





(ng/g lipid) Cases, n Controls, n
Multivariate-adjusteda
OR (95% CI)
1 (16.6–24.9) DDE 	458.25 117 83 1.00
458.26–951.82 90 74 0.87 (0.56–1.35)
951.83–11,818.78 80 52 1.15 (0.67–1.98)
Peak-4 PCBs 	308.34 90 65 1.00
308.35–472.45 96 74 0.96 (0.61–1.52)
462.46–3,287.34 98 68 1.17 (0.71–1.95)
Chlordane 	79.18 91 71 1.00
79.19–125.53 88 67 1.03 (0.66–1.62)
125.54–473.08 85 58 1.13 (0.69–1.87)
2 (25.0–29.9) DDE 	458.25 54 34 1.00
458.26–951.82 61 31 1.09 (0.58–2.05)
951.83–11,818.78 86 47 0.94 (0.49–1.80)
Peak-4 PCBs 	308.34 70 36 1.00
308.35–472.45 57 31 0.77 (0.41–1.45)
462.46–3,287.34 75 44 0.69 (0.38–1.27)
Chlordane 	79.18 52 30 1.00
79.19–125.53 63 26 1.30 (0.66–2.53)
125.54–473.08 78 46 0.73 (0.38–1.42)
3 (30.0–62.6) DDE 	458.25 31 22 1.00
458.26–951.82 36 34 0.70 (0.33–1.50)
951.83–11,818.78 68 40 1.17 (0.54–2.55)
Peak-4 PCBs 	308.34 55 37 1.00
308.35–472.45 38 32 0.72 (0.37–1.39)
462.46–3,287.34 39 26 0.85 (0.40–1.80)
Chlordane 	79.18 36 28 1.00
79.19–125.53 35 35 0.68 (0.33–1.42)
125.54–473.08 49 27 1.17 (0.54–2.50)
a DDE and Peak-4 PCB analyses were adjusted for age, race, history of fertility problems, and history of benign breast disease. Chlordane analyses were adjusted for age,
race, history of fertility problems, and gravidity.
b Adjusted using method 2 as described by Phillips et al. (50).
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Table 6 Multivariate-adjusteda ORs and 95% CIs for breast cancer in relation to lipid-adjustedb log-transformed serum levels of organochlorine compounds stratified




(ng/g lipid) Cases, n Controls, n
Multivariate-adjusteda
OR (95% CI)
Age at reference date
	65 years DDE 	458.25 177 129 1.00
458.26–951.82 138 113 0.86 (0.60–1.23)
951.83–11,818.78 106 78 1.15 (0.75–1.76)
Peak-4 PCBs 	308.34 179 129 1.00
308.35–472.45 137 108 0.92 (0.65–1.31)
462.46–3,287.34 104 79 1.08 (0.72–1.61)
Chlordane 	79.18 149 113 1.00
79.19–125.53 140 102 1.08 (0.75–1.56)
125.54–473.08 100 83 0.96 (0.63–1.45)
65 years DDE 	458.25 25 10 1.00
458.26–951.82 49 26 0.81 (0.34–1.98)
951.83–11,818.78 128 61 0.91 (0.40–2.06)
Peak-4 PCBs 	308.34 36 9 1.00
308.35–472.45 54 29 0.42 (0.17–1.01)
462.46–3,287.34 108 59 0.42 (0.19–0.96)
Chlordane 	79.18 30 16 1.00
79.19–125.53 46 26 0.95 (0.44–2.06)
125.54–473.08 113 48 1.26 (0.62–2.56)
Menopausal status
Premenopausal DDE 	458.25 110 75 1.00
458.26–951.82 72 48 0.95 (0.57–1.57)
951.83–11,818.78 30 23 0.86 (0.44–1.71)
Peak-4 PCBs 	308.34 101 73 1.00
308.35–472.45 73 43 1.22 (0.74–2.03)
462.46–3,287.34 36 27 0.94 (0.51–1.74)
Chlordane 	79.18 91 71 1.00
79.19–125.53 68 42 1.35 (0.80–2.28)
125.54–473.08 32 22 1.11 (0.56–2.17)
Postmenopausal DDE 	458.25 85 55 1.00
458.26–951.82 115 85 0.81 (0.52–1.27)
951.83–11,818.78 99 112 1.10 (0.70–1.74)
Peak-4 PCBs 	308.34 109 55 1.00
308.35–472.45 113 87 0.59 (0.38–0.92)
462.46–3,287.34 174 109 0.73 (0.47–1.12)
Chlordane 	79.18 85 55 1.00
79.19–125.53 112 78 0.92 (0.59–1.46)
125.54–473.08 79 101 1.09 (0.70–1.69)
Years of residence on Long Island
	15 years DDE 	458.25 31 28 1.00
458.26–951.82 31 19 1.47 (0.66–3.28)
951.83–11,818.78 40 19 2.13 (0.81–5.60)
Peak-4 PCBs 	308.34 35 27 1.00
308.35–472.45 32 23 1.09 (0.51–2.34)
462.46–3,287.34 34 16 1.52 (0.64–3.62)
Chlordane 	79.18 37 23 1.00
79.19–125.53 29 22 0.70 (0.31–1.55)
125.54–473.08 29 14 1.12 (0.46–2.73)
15 years DDE 	458.25 171 111 1.00
458.26–951.82 156 120 0.76 (0.53–1.08)
951.83–11,818.78 194 120 0.94 (0.64–1.38)
Peak-4 PCBs 	308.34 179 111 1.00
308.35–472.45 159 114 0.80 (0.56–1.13)
462.46–3,287.34 178 122 0.83 (0.58–1.20)
Chlordane 	79.18 142 106 1.00
79.19–125.53 157 106 1.09 (0.76–1.56)
125.54–473.08 183 117 1.06 (0.73–1.56)
a DDE and Peak-4 PCB analyses were adjusted for age, race, history of fertility problems, and history of benign breast disease. Chlordane analyses were adjusted for age,
race, history of fertility problems, and gravidity.
b Adjusted using method 2 as described by Phillips et al. (50).
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Table 7 Multivariate-adjusteda ORs and 95% CIs for breast cancer in relation to lipid-adjustedb log-transformed serum levels of organochlorine compounds stratified











In situ DDE 	458.25 60 136 1.00
458.26–951.82 55 139 0.91 (0.58–1.17)
951.83–11,818.78 59 139 1.09 (0.66–1.80) 0.51
Peak-4 PCBs 	308.34 59 138 1.00
308.35–472.45 53 137 0.93 (0.59–1.46)
462.46–3,287.34 62 138 1.18 (0.74–1.90) 0.93
Chlordane 	79.18 67 129 1.00
79.19–125.53 50 128 0.75 (0.48–1.18)
125.54–473.08 45 131 1.18 (0.82–1.69) 0.02
Invasive DDE 	458.25 142 136 1.00
458.26–951.82 132 139 0.82 (0.58–1.17)
951.83–11,818.78 175 139 1.06 (0.73–1.56) 0.92
Peak-4 PCBs 	308.34 156 138 1.00
308.35–472.45 138 137 0.81 (0.58–1.14)
462.46–3,287.34 150 138 0.82 (0.57–1.18) 0.21
Chlordane 	79.18 112 129 1.00
79.19–125.53 136 128 0.66 (0.40–1.08)
125.54–473.08 167 131 1.28 (0.88–1.88) 0.87
ER-PR status
ERPR DDE 	458.25 65 139 1.00
458.26–951.82 60 139 0.80 (0.51–1.25)
951.83–11,818.78 83 139 1.10 (0.69–1.77) 0.94
Peak-4 PCBs 	308.34 65 138 1.00
308.35–472.45 70 137 0.98 (0.63–1.50)
462.46–3,287.34 71 138 0.95 (0.60–1.51) 0.28
Chlordane 	79.18 52 129 1.00
79.19–125.53 67 128 1.21 (0.77–1.91)
125.54–473.08 74 131 1.14 (0.70–1.84) 0.95
ERPR DDE 	458.25 14 139 1.00
458.26–951.82 12 139 0.61 (0.26–1.40)
951.83–11,818.78 19 139 0.70 (0.20–2.45) 0.44
Peak-4 PCBs 	308.34 12 138 1.00
308.35–472.45 16 137 1.04 (0.46–2.36)
462.46–3,287.34 16 138 0.81 (0.34–1.95) 0.16
Chlordane 	79.18 10 129 1.00
79.19–125.53 14 128 1.39 (0.58–3.32)
125.54–473.08 17 131 1.18 (0.48–2.93) 0.1
ERPR DDE 	458.25 7 139 1.00
458.26–951.82 7 139 1.05 (0.34–3.21)
951.83–11,818.78 7 139 1.24 (0.35–4.37) 0.65
Peak-4 PCBs 	308.34 6 138 1.00
308.35–472.45 7 137 1.42 (0.45–4.50)
462.46–3,287.34 8 138 1.94 (0.58–6.50) 0.64
ERPR Chlordane 	79.18 8 129 1.00
79.19–125.53 6 128 0.72 (0.24–2.23)
125.54–473.08 5 131 0.53 (0.15–1.90) 0.75
ERPR DDE 	458.25 29 139 1.00
458.26–951.82 22 139 0.74 (0.40–1.38)
951.83–11,818.78 29 139 0.95 (0.48–1.86) 0.47
Peak-4 PCBs 	308.34 37 138 1.00
308.35–472.45 22 137 0.56 (0.31–1.03)
462.46–3,287.34 20 138 0.46 (0.24–0.90) 0.25
Chlordane 	79.18 23 129 1.00
79.19–125.53 22 128 1.02 (0.53–1.94)
125.54–473.08 30 131 1.37 (0.70–2.66) 0.84
a DDE and Peak-4 PCB analyses were adjusted for age, race, history of fertility problems, and history of benign breast disease. Chlordane analyses were adjusted for age,
race, history of fertility problems, and gravidity.
b Adjusted using method 2 as described by Phillips et al. (50).
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In conclusion, in this large population-based case-control
study among women on Long Island, breast cancer risk was not
increased in relation to serum organochlorine levels. These
observations are consistent with most of the recent studies
conducted in the United States (67) and elsewhere. Thus, it
seems unlikely that breast cancer risk is associated with or-
ganorchlorines when measured close to the time of breast
cancer diagnosis. These data do not rule out the possibility,
however, that breast cancer risk is elevated by high organo-
chlorine exposures several decades earlier that, through varia-
tions in individual metabolism, now measure as low body-
burden levels. Also, very limited data recently suggest that
breast cancer mortality may be associated with some organo-
chlorine compounds (66). These possibilities require additional
research.
Any future research on the role of organochlorines in
breast cancer development must take into consideration that
these compounds are not complete carcinogens and, thus, prob-
ably act in tumor promotion and progression in concert with
other cofactors (including tumor initiators, DNA repair insuf-
ficiency, and viral exposures), as has been postulated for non-
Hodgkin’s lymphoma (68). Current measurement of organo-
chlorines in case-control studies probably reflects their activity
as late-stage promoters, possibly only within the window of
time between postpregnancy to diagnosis (33, 69). To move the
field forward, studies should be of sufficient size to examine
potential interactions and should include assessment of the
potential cofactors with which organochlorines may interact.
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